JP2024514009A5 - - Google Patents
Info
- Publication number
- JP2024514009A5 JP2024514009A5 JP2023563841A JP2023563841A JP2024514009A5 JP 2024514009 A5 JP2024514009 A5 JP 2024514009A5 JP 2023563841 A JP2023563841 A JP 2023563841A JP 2023563841 A JP2023563841 A JP 2023563841A JP 2024514009 A5 JP2024514009 A5 JP 2024514009A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- nhc
- heteroaryl
- cycloalkyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024199756A JP2025015696A (ja) | 2021-04-21 | 2024-11-15 | カルボキシ-ベンズイミダゾールglp-1r調節化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177778P | 2021-04-21 | 2021-04-21 | |
| US63/177,778 | 2021-04-21 | ||
| US202163286475P | 2021-12-06 | 2021-12-06 | |
| US63/286,475 | 2021-12-06 | ||
| PCT/US2022/025364 WO2022225941A1 (en) | 2021-04-21 | 2022-04-19 | Carboxy-benzimidazole glp-1r modulating compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199756A Division JP2025015696A (ja) | 2021-04-21 | 2024-11-15 | カルボキシ-ベンズイミダゾールglp-1r調節化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024514009A JP2024514009A (ja) | 2024-03-27 |
| JP2024514009A5 true JP2024514009A5 (cg-RX-API-DMAC10.html) | 2024-04-15 |
| JP7600433B2 JP7600433B2 (ja) | 2024-12-16 |
Family
ID=81654570
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563841A Active JP7600433B2 (ja) | 2021-04-21 | 2022-04-19 | カルボキシ-ベンズイミダゾールglp-1r調節化合物 |
| JP2024199756A Pending JP2025015696A (ja) | 2021-04-21 | 2024-11-15 | カルボキシ-ベンズイミダゾールglp-1r調節化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199756A Pending JP2025015696A (ja) | 2021-04-21 | 2024-11-15 | カルボキシ-ベンズイミダゾールglp-1r調節化合物 |
Country Status (26)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20220178A (es) | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| SI4097097T1 (sl) | 2020-01-29 | 2025-04-30 | Gilead Sciences, Inc. | Spojine, ki modulirajo glp-1r |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| US12180197B2 (en) | 2021-03-11 | 2024-12-31 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| LT4271672T (lt) | 2021-04-21 | 2026-03-10 | Gilead Sciences, Inc. | Karboksibenzimidazolo junginiai, moduliuojantys glp-1r |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| CN119907794A (zh) | 2022-09-22 | 2025-04-29 | 盐野义制药株式会社 | 具有glp-1受体激动剂作用的稠环化合物 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| CR20250178A (es) | 2022-11-16 | 2025-06-06 | Lilly Co Eli | Agonistas del receptor del péptido-1 similar al glucagón |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂,其制备方法和应用 |
| EP4731245A1 (en) * | 2023-06-23 | 2026-04-29 | Merck Sharp & Dohme LLC | Use of a long-acting oxyntomodulin derivative for treament of fatty liver disease |
| WO2025021048A1 (zh) * | 2023-07-21 | 2025-01-30 | 石药集团中奇制药技术(石家庄)有限公司 | 一类多环化合物及其用途 |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2026033382A1 (en) * | 2024-08-07 | 2026-02-12 | Pfizer Inc. | Heterocyclic glp-1r modulators |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000008015A2 (en) | 1998-08-07 | 2000-02-17 | Applied Research Systems Ars Holding N.V. | Fsh mimetics for the treatment of infertility |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US20030134853A1 (en) | 2001-09-26 | 2003-07-17 | Priestley Eldon Scott | Compounds useful for treating hepatitis C virus |
| CA2523743A1 (en) | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
| AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
| WO2004108672A1 (en) | 2003-06-02 | 2004-12-16 | Abbott Laboratories | Isoindolin-1-one compounds as kinase inhibitors |
| WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用 |
| EP1844043A2 (en) | 2004-11-18 | 2007-10-17 | The Institutes for Pharmaceutical Discovery, LLC | Heterocycle substituted carboxylic acids for the treatment of diabetes |
| EP1838690A2 (en) | 2004-12-21 | 2007-10-03 | Devgen N.V. | Compounds with kv4 ion channel activity |
| PL1940786T3 (pl) | 2005-09-16 | 2010-12-31 | Arrow Therapeutics Ltd | Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C |
| WO2007115077A2 (en) | 2006-03-31 | 2007-10-11 | Astrazeneca Ab | Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators |
| WO2008033455A2 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors |
| EA018225B1 (ru) | 2008-03-07 | 2013-06-28 | Транстек Фарма, Инк. | Соединения оксадиазоантрацена для лечения диабета |
| WO2010029299A1 (en) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Pyrimidinone derivaties for use as medicaments |
| US20110294853A1 (en) | 2008-09-12 | 2011-12-01 | Benjamin Pelcman | Bis Aromatic Compounds for Use in the Treatment of Inflammation |
| WO2010046780A2 (en) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
| CN103221404B (zh) | 2010-05-13 | 2015-12-16 | 安姆根有限公司 | 可用作pde10抑制剂的不饱和氮杂环化合物 |
| WO2011156655A2 (en) | 2010-06-09 | 2011-12-15 | Receptos, Inc. | Novel glp-1 receptor stabilizers and modulators |
| AU2011270994B2 (en) | 2010-06-24 | 2015-12-10 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors |
| EP2744807A4 (en) | 2011-08-15 | 2015-03-04 | Intermune Inc | COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS |
| CN103059014B (zh) | 2011-10-21 | 2016-05-18 | 北京韩美药品有限公司 | 新型杂芳基氨基衍生物 |
| CN104080767A (zh) | 2011-12-12 | 2014-10-01 | 瑞塞普托斯公司 | 新的glp-1受体调节剂 |
| CA2874303C (en) | 2012-06-11 | 2020-10-13 | Ucb Biopharma Sprl | Tnf -alpha modulating benz imidazoles |
| WO2016018701A1 (en) | 2014-07-28 | 2016-02-04 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| KR20160066490A (ko) | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
| ES2907461T3 (es) | 2015-01-20 | 2022-04-25 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos |
| US20170035881A1 (en) | 2015-10-19 | 2017-02-09 | Acerta Pharma B.V. | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| MX2018011716A (es) | 2016-03-30 | 2019-02-18 | Ishihara Sangyo Kaisha | Compuesto de piridazinona o su sal, y herbicida que lo contiene. |
| WO2018109607A1 (en) | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CA3058182A1 (en) | 2017-03-27 | 2018-10-04 | Cardurion Pharmaceuticals, Llc | Heterocyclic compound |
| EP3681499A4 (en) | 2017-09-13 | 2021-04-21 | D.E. Shaw Research, LLC | CONNECTIONS AS RAS INHIBITORS AND THEIR USE |
| WO2019217165A1 (en) | 2018-05-08 | 2019-11-14 | Vtv Therapeutics Llc | Therapeutic uses of glp1r agonists |
| CA3045644C (en) | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| FI3806855T3 (fi) | 2018-06-15 | 2023-05-04 | Pfizer | Glp-1 -reseptorin agonisteja ja niiden käyttöjä |
| US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
| EA202191432A1 (ru) | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| AU2020256647B2 (en) * | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| CN112294760B (zh) | 2019-07-26 | 2025-12-12 | 宁波新致生物科技有限公司 | 一种液体制剂及其应用 |
| WO2021018023A1 (zh) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| CN112409331B (zh) | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| CR20220178A (es) * | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| KR102841983B1 (ko) | 2019-11-04 | 2025-08-04 | 주식회사 엘지화학 | 광변조 디바이스의 제조 방법 |
| ES3029360T3 (en) | 2019-11-15 | 2025-06-24 | Ildong Pharmaceutical Co Ltd | Glp-1 receptor agonist and use thereof |
| EP4069686B1 (en) | 2019-12-02 | 2025-01-22 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
| SI4097097T1 (sl) | 2020-01-29 | 2025-04-30 | Gilead Sciences, Inc. | Spojine, ki modulirajo glp-1r |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| CN115697999A (zh) | 2020-02-13 | 2023-02-03 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| MX2022011349A (es) | 2020-03-18 | 2022-11-10 | Lg Chemical Ltd | Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo. |
| MX2022010811A (es) | 2020-03-27 | 2022-09-27 | Pfizer | Tratamiento de la diabetes tipo 2 u obesidad o sobrepeso con el acido 2-[(4-{6-[(4-ciano-2-fluorobencil)oxi]piridin-2-il}piperidin -1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-bencimidazol-6-carboxil ico o una sal farmaceutica del mismo. |
| CN113493447B (zh) | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| PT4157832T (pt) | 2020-05-27 | 2024-07-30 | Qilu Regor Therapeutics Inc | Formas de sal e cristal de agonistas de glp-1r e utilizações dos mesmos |
| PH12022553313A1 (en) | 2020-06-04 | 2023-04-12 | Hangzhou Sciwind Biosciences Co Ltd | Five-membered heteroaromatic imidazole compound and use thereof |
| CN113816948B (zh) | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| TW202214622A (zh) | 2020-08-06 | 2022-04-16 | 大陸商上海齊魯銳格醫藥研發有限公司 | Glp-1r促效劑及其用途 |
| JP2023538408A (ja) | 2020-08-21 | 2023-09-07 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Glp-1r作動薬としての化合物 |
| CN115515956B (zh) | 2020-09-29 | 2024-06-25 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| CN116348464B (zh) | 2020-10-12 | 2026-06-16 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022111624A1 (zh) | 2020-11-27 | 2022-06-02 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| CA3211349A1 (en) | 2021-03-09 | 2022-09-15 | Basf Se | Tricyclic pesticidal compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US12180197B2 (en) | 2021-03-11 | 2024-12-31 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| US20240300928A1 (en) | 2021-04-08 | 2024-09-12 | Lg Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| EP4271674B9 (en) | 2021-04-21 | 2026-03-11 | Gilead Sciences, Inc. | Carboxy-benzimidazole glp-1r modulating compounds |
| TW202304500A (zh) | 2021-04-21 | 2023-02-01 | 瑞士商諾華公司 | 升糖素樣肽化合物 |
| LT4271672T (lt) | 2021-04-21 | 2026-03-10 | Gilead Sciences, Inc. | Karboksibenzimidazolo junginiai, moduliuojantys glp-1r |
| CN117098758A (zh) | 2021-06-24 | 2023-11-21 | 杭州中美华东制药有限公司 | Glp-1受体激动剂及其组合物和用途 |
| CN113480534B (zh) | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| IL312132A (en) | 2021-11-30 | 2024-06-01 | Kura Oncology Inc | Macrocyclic compounds having farnesyltransferase inhibitory activity |
-
2022
- 2022-04-19 LT LTEPPCT/US2022/025364T patent/LT4271672T/lt unknown
- 2022-04-19 FI FIEP22723851.6T patent/FI4271672T3/fi active
- 2022-04-19 PL PL22723851.6T patent/PL4271672T3/pl unknown
- 2022-04-19 JP JP2023563841A patent/JP7600433B2/ja active Active
- 2022-04-19 AU AU2022263410A patent/AU2022263410B2/en active Active
- 2022-04-19 PE PE2023002895A patent/PE20240362A1/es unknown
- 2022-04-19 KR KR1020267020718A patent/KR20260110277A/ko active Pending
- 2022-04-19 IL IL306110A patent/IL306110A/en unknown
- 2022-04-19 MX MX2023012418A patent/MX2023012418A/es unknown
- 2022-04-19 CN CN202280029546.2A patent/CN117279905B/zh active Active
- 2022-04-19 BR BR112023021561A patent/BR112023021561A2/pt unknown
- 2022-04-19 PT PT227238516T patent/PT4271672T/pt unknown
- 2022-04-19 KR KR1020237039911A patent/KR102985076B1/ko active Active
- 2022-04-19 DK DK22723851.6T patent/DK4271672T3/da active
- 2022-04-19 PH PH1/2023/552860A patent/PH12023552860A1/en unknown
- 2022-04-19 ES ES22723851T patent/ES3071339T3/es active Active
- 2022-04-19 SI SI202230242T patent/SI4271672T1/sl unknown
- 2022-04-19 WO PCT/US2022/025364 patent/WO2022225941A1/en not_active Ceased
- 2022-04-19 EP EP25207471.1A patent/EP4691554A3/en active Pending
- 2022-04-19 HR HRP20260177TT patent/HRP20260177T1/hr unknown
- 2022-04-19 US US17/724,212 patent/US11858918B2/en active Active
- 2022-04-19 CA CA3216163A patent/CA3216163A1/en active Pending
- 2022-04-19 CR CR20230495A patent/CR20230495A/es unknown
- 2022-04-19 EP EP22723851.6A patent/EP4271672B1/en active Active
- 2022-04-20 TW TW112149368A patent/TWI919156B/zh active
- 2022-04-20 TW TW111114936A patent/TWI828119B/zh active
-
2023
- 2023-10-19 CO CONC2023/0013757A patent/CO2023013757A2/es unknown
- 2023-10-19 CL CL2023003119A patent/CL2023003119A1/es unknown
- 2023-10-19 DO DO2023000232A patent/DOP2023000232A/es unknown
- 2023-10-27 US US18/496,137 patent/US12570642B2/en active Active
-
2024
- 2024-10-08 AU AU2024227155A patent/AU2024227155A1/en active Pending
- 2024-11-15 JP JP2024199756A patent/JP2025015696A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024514010A5 (cg-RX-API-DMAC10.html) | ||
| HRP20250415T1 (hr) | Modulirajući spojevi karboksi-benzimidazola glp-1r | |
| JP2023513272A5 (cg-RX-API-DMAC10.html) | ||
| JP2023540609A5 (cg-RX-API-DMAC10.html) | ||
| JP2023546054A5 (cg-RX-API-DMAC10.html) | ||
| JP2023540558A5 (cg-RX-API-DMAC10.html) | ||
| JP2023546055A5 (cg-RX-API-DMAC10.html) | ||
| JP2023515404A5 (cg-RX-API-DMAC10.html) | ||
| ES2713566T3 (es) | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II | |
| JP2019069940A (ja) | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 | |
| US20120046305A1 (en) | Methods and compositions for treating respiratory disorders | |
| JP2019517478A5 (cg-RX-API-DMAC10.html) | ||
| AU2011237421B2 (en) | Inverse agonists and neutral antagonists for the TSH receptor | |
| JP2018530571A5 (cg-RX-API-DMAC10.html) | ||
| TWI224102B (en) | Serotonergic agents | |
| JP2007519753A5 (cg-RX-API-DMAC10.html) | ||
| KR20110067096A (ko) | 당뇨병 및 관련 상태를 치료하기 위한 병용 요법 | |
| US20160115149A1 (en) | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| KR20090088854A (ko) | 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도 | |
| JP2015536973A (ja) | PDE4阻害剤とPI3δ阻害剤または二重PI3δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| JP2022501429A5 (cg-RX-API-DMAC10.html) | ||
| TWI842924B (zh) | Gpr119致效劑及dpp-4抑制劑的藥物組合及藥物套組 | |
| TWI568733B (zh) | 新穎的唏及1,1a,2,7b-四氫環丙烷[c]唏吡啶并吡化合物 | |
| CN121985948A (zh) | Glp-1r激动剂的制剂及其制备方法 | |
| JP2023500685A5 (cg-RX-API-DMAC10.html) |